These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
450 related articles for article (PubMed ID: 22703861)
1. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Patil HR; Al Badarin FJ; Al Shami HA; Bhatti SK; Lavie CJ; Bell DS; O'Keefe JH Am J Cardiol; 2012 Sep; 110(6):826-33. PubMed ID: 22703861 [TBL] [Abstract][Full Text] [Related]
2. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis. Savarese G; D'Amore C; Federici M; De Martino F; Dellegrottaglie S; Marciano C; Ferrazzano F; Losco T; Lund LH; Trimarco B; Rosano GM; Perrone-Filardi P Int J Cardiol; 2016 Oct; 220():595-601. PubMed ID: 27390996 [TBL] [Abstract][Full Text] [Related]
3. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. White WB; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Fleck P; Heller S; Mehta C; Nissen SE; Perez A; Wilson C; Zannad F Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652 [TBL] [Abstract][Full Text] [Related]
4. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Gooßen K; Gräber S Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906 [TBL] [Abstract][Full Text] [Related]
5. Cardiovascular outcome trials of glucose-lowering medications: an update. Home P Diabetologia; 2019 Mar; 62(3):357-369. PubMed ID: 30607467 [TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. White WB; Pratley R; Fleck P; Munsaka M; Hisada M; Wilson C; Menon V Diabetes Obes Metab; 2013 Jul; 15(7):668-73. PubMed ID: 23489301 [TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials. Elgendy IY; Mahmoud AN; Barakat AF; Elgendy AY; Saad M; Abuzaid A; Wayangankar SA; Bavry AA Am J Cardiovasc Drugs; 2017 Apr; 17(2):143-155. PubMed ID: 27873238 [TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis. Chen M; Liu Y; Jin J; He Q Ren Fail; 2016; 38(4):581-7. PubMed ID: 26915531 [TBL] [Abstract][Full Text] [Related]
9. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus. Davidson MH Postgrad Med; 2014 May; 126(3):56-65. PubMed ID: 24918792 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies. Scheen AJ Diabetes Metab; 2018 Nov; 44(5):386-392. PubMed ID: 30126735 [TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Wu S; Hopper I; Skiba M; Krum H Cardiovasc Ther; 2014 Aug; 32(4):147-58. PubMed ID: 24750644 [TBL] [Abstract][Full Text] [Related]
12. Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox. Green JB Postgrad Med; 2014 May; 126(3):190-204. PubMed ID: 24918803 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis. Savarese G; Perrone-Filardi P; D'Amore C; Vitale C; Trimarco B; Pani L; Rosano GM Int J Cardiol; 2015 Feb; 181():239-44. PubMed ID: 25528528 [TBL] [Abstract][Full Text] [Related]
14. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Min SH; Yoon JH; Hahn S; Cho YM Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197 [TBL] [Abstract][Full Text] [Related]
16. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety. Green JB Postgrad Med; 2012 Jul; 124(4):54-61. PubMed ID: 22913894 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Scheen AJ Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503 [TBL] [Abstract][Full Text] [Related]
18. [DPP4 inhibitors: what is the cardiovascular risk?]. Langrand C; Moulin P Rev Prat; 2015 Oct; 65(8):1039-41. PubMed ID: 26749701 [No Abstract] [Full Text] [Related]
19. Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials. Kappel BA; Marx N; Federici M Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):697-705. PubMed ID: 26164634 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. Frandsen CS; Madsbad S Diabet Med; 2014 Nov; 31(11):1293-300. PubMed ID: 25112609 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]